Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 1:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 452 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Amyotrophic Lateral Sclerosis ALS Clear all
Terminated No phase listed Observational

Pennsylvania Consortium: Clinical Database

NCT00718445
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Neurodegenerative Disease, Motor Neuron Disease
Interventions
Not listed
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years to 89 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Oct 6, 2026, 1:50 AM EDT
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen A Zilucoplan

NCT04436497
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Zilucoplan, Matching Placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 6, 2026, 1:50 AM EDT
Completed Phase 1 Interventional

CNS10-NPC-GDNF for the Treatment of ALS

NCT02943850
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Stem cell (HPC) implantation, Stereotactic surgical device
Biological · Device
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 6, 2026, 1:50 AM EDT
Completed No phase listed Observational

A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers

NCT01495390
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Nervous System Diseases, Sclerosis, Motor Neuron Disease, Spinal Cord Diseases, Central Nervous System Diseases, Neurodegenerative Diseases, Neuromuscular Diseases, ALS
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
6
States / cities
Phoenix, Arizona • Jacksonville, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 6, 2026, 1:50 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)

NCT03068754
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Acthar, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 75 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
39
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 6, 2026, 1:50 AM EDT
Withdrawn Phase 2 Interventional

A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS

NCT00561366
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Placebo, Arimoclomol
Drug
Lead sponsor
CytRx
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
31
States / cities
Pacific Palisades, California • San Francisco, California • Denver, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2012 · Synced Oct 6, 2026, 1:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Developing a Discrimination Model to Diagnose ALS

NCT01995903
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
MRI(magnetic resonance imaging)
Diagnostic Test
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 6, 2026, 1:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

EEG-Based Brain-Computer Interface Project for Individuals With Amyotrophic Lateral Sclerosis (ALS)

NCT00718458
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Neurodegenerative Disease, Motor Neuron Disease
Interventions
Not listed
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years to 90 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 6, 2026, 1:50 AM EDT
Completed Phase 1 Interventional

Ciprofloxacin/Celecoxib Combination in Patients With ALS

NCT04090684
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
Fixed dose combination Ciprofloxacin/Celecoxib
Drug
Lead sponsor
NeuroSense Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Oct 6, 2026, 1:50 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Treatment of ALS

NCT04681118
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
NurOwn (MSC-NTF cells)
Biological
Lead sponsor
Brainstorm-Cell Therapeutics
Industry
Eligibility
18 Years to 63 Years
U.S. locations
5
States / cities
Irvine, California • San Francisco, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 6, 2026, 1:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

PET Imaging in ALS Patients

NCT02236897
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
PET Scanning
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 6, 2026, 1:50 AM EDT
Completed Phase 1 Interventional Results available

A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)

NCT02288091
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Inosine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 6, 2026, 1:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

ALS Testing Through Home-based Outcome Measures

NCT03016897
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
Other
Lead sponsor
Jeremy Shefner
Other
Eligibility
18 Years to 85 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 6, 2026, 1:50 AM EDT
Completed No phase listed Observational

Muscle Ultrasound: A New Tool for Measuring Progression in Amyotrophic Lateral Sclerosis (ALS)

NCT00838617
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 11, 2009 · Synced Oct 6, 2026, 1:50 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Intermuscular Coherence as a Biomarker for ALS

NCT05104710
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
20 Years to 90 Years
Enrollment
650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
4
States / cities
Irvine, California • Miami, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 6, 2026, 1:50 AM EDT
Completed Phase 2 Interventional Results available

Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)

NCT01709149
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
CK-2017357, Placebo tablets, Riluzole
Drug · Other
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years and older
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
44
States / cities
Phoenix, Arizona • La Jolla, California • Orange, California + 38 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 6, 2026, 1:50 AM EDT
Recruiting Phase 2 Interventional

PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

NCT07142291
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Cromolyn Sodium (34.2 mg BID), Cromolyn Sodium (17.1 mg BID), Placebo, Riluzole (100 mg)
Drug
Lead sponsor
PhenoNet, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Scottsdale, Arizona • La Jolla, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 6, 2026, 1:50 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Studies in Amyotrophic Lateral Sclerosis (ALS) and Other Neurodegenerative Motor Neuron Disorders

NCT05474235
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2038
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 6, 2026, 1:50 AM EDT
Not listed Not applicable Interventional

EMPOWER Early Feasibility Study: Non-invasive BCI to Control a Wheelchair for People With Paralysis

NCT06169696
View directory record Official record
Conditions
Neurologic Disorder, Paralysis, Paralysis; Stroke, Amyotrophic Lateral Sclerosis, Spinal Cord Injuries, Cervical Spinal Cord Injury, Tetraplegic; Paralysis, Quadriplegia/Tetraplegia
Interventions
Intervention/Treatment
Device
Lead sponsor
Synaptrix Labs Inc.
Industry
Eligibility
21 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Oct 6, 2026, 1:50 AM EDT
Recruiting No phase listed Observational

A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)

NCT07259980
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Tofersen
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 6, 2026, 1:50 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

PRE-Symptomatic Studies in Amyotrophic Lateral Sclerosis

NCT01508962
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2037
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 6, 2026, 1:50 AM EDT
Completed Not applicable Interventional Results available

Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation

NCT00116558
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Early NIPPV, Standard NIPPV
Device
Lead sponsor
Edward Kasaraskis
Other
Eligibility
18 Years to 80 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
12
States / cities
Denver, Colorado • Miami, Florida • Lexington, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 6, 2026, 1:50 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Study to Evaluate the Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With ALS

NCT03338114
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Fasciculation
Interventions
FLX-787-ODT (orally disintigrating tablet)
Drug
Lead sponsor
Flex Pharma, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 6, 2026, 1:50 AM EDT
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose

NCT05136885
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
SLS-005, Matching Placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 6, 2026, 1:50 AM EDT